Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hubei Goto Biopharm Co (300966) Fair Value & Analysis

Healthcare · CN · Market cap 3.0B CNY

Price¥27.10
Fair Value¥32.25
Upside+19.0%
Quality91/100
Evidence: Low Range ¥24.19 – ¥40.31

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Hubei Goto Biopharm Co (300966) currently trades at ¥27.10, while our model-based Fair Value estimate is ¥32.25 — implying the stock looks roughly 19.0% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Hubei Goto Biopharm Co (300966) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥32.25 versus a price of ¥27.10 — about +19% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 300966?
Our 21-model fair value for Hubei Goto Biopharm Co is ¥32.25 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥27.10.
What is the quality score of 300966?
Hubei Goto Biopharm Co has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.